Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics... Show more
Zymeworks Inc. is a clinical-stage biotechnology company that has deliberately repositioned itself around what management calls an "asset and royalty aggregation" strategy. Rather than building a large commercial salesforce, the company engineers differentiated antibody-based therapies and licenses them to larger partners, retaining milestones and tiered royalties. This model is anchored by Ziihera, a HER2-targeted bispecific antibody discovered using Zymeworks' proprietary Azymetric technology, which is partnered with Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene).
The competitive advantage lies in the company's fully integrated antibody engineering engine, spanning bispecific antibodies, ADCs (antibody-drug conjugates, which link a targeting antibody to a cell-killing payload), and trispecific T-cell engagers. This platform breadth gives Zymeworks multiple shots on goal across oncology and inflammatory disease. The trade-off is structural: because revenue is dependent on partner commercialization and milestone achievement, top-line growth is lumpy, and near-term sales remain small relative to the company's market capitalization.
The most significant near-term driver is the commercial launch of zanidatamab in first-line HER2-positive GEA by Jazz, following the U.S. approval and the associated $250 million milestone. Investor attention now shifts to launch trajectory and the second interim overall survival analysis from the pivotal HERIZON-GEA-01 trial, which could further de-risk the asset's durability.
In parallel, a supplemental Biologics License Application (sBLA) in China remains under review, with an additional milestone payment tied to potential approval there. The anticipated closing of the Theravance Biopharma acquisition represents a strategic inflection point, as it would immediately expand Zymeworks' royalty and cash-flow profile under the aggregation strategy. Early data readouts for ZW191, a folate receptor alpha-targeting ADC granted FDA Fast Track designation for platinum-resistant ovarian cancer, and progression of the pan-RAS oncology program (ZW209 and related candidates) are also on the 2026–2027 horizon.
On the analyst front, sentiment has turned broadly constructive. H.C. Wainwright maintains a Buy rating with a $46 price target, J.P. Morgan holds an Overweight rating (a positive stance) with a $33 target, and Citi initiated an "upside catalyst watch" with a Buy rating and a $37 target. Truist Securities initiated coverage with a Buy rating, and the wider consensus skews heavily toward Buy recommendations with no widely cited Sell ratings.
Zymeworks operates in the oncology-focused biotechnology sector, where demand is driven less by discretionary consumer cycles and more by unmet medical need and demographic trends such as aging populations. This insulates the company from inflation-sensitive consumer spending, but it remains exposed to biotechnology financing conditions. Interest rates matter because clinical-stage companies often depend on external capital; Zymeworks' roughly $400 million cash position and cash runway beyond 2028, supplemented by a $250 million non-recourse royalty loan, reduce near-term dilution risk.
The regulatory climate is a key sensitivity. The FDA's receptiveness to bispecific antibodies and ADCs, and the evolving competitive landscape in HER2-directed therapies, will shape both commercialization and future licensing opportunities. Geopolitical factors, including U.S.–China regulatory dynamics, also influence the timing of the China sBLA decision and associated milestones.
For traders seeking a data-driven view of where ZYME shares may head next, Tickeron's Trend Prediction Engine offers an AI-powered forecasting tool designed to help identify whether a stock, ETF (exchange-traded fund), or other asset may trend bullish, bearish, or sideways over the coming week or month. The tool is built to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments, with searchable prediction categories, historical context, and alert-oriented functionality. Investors can use it to complement fundamental research on ZYME's catalysts with a systematic view of price momentum.
Looking ahead, Zymeworks' trajectory hinges on converting regulatory wins into recurring royalty revenue. Management has guided to 2026 revenue of roughly $278 million to $292 million, a figure that reflects expected milestone receipts rather than organic product sales, underscoring the milestone-dependent nature of the model. The transition to a royalty-aggregation structure is designed to improve earnings quality and margin sustainability over time, but it also concentrates near-term outcomes on partner execution.
Longer term, the company's wholly owned ADC and T-cell engager pipeline represents the next growth engine, while the pan-RAS program targets a historically "undruggable" oncogene with substantial market potential. Cost-structure evolution, disciplined capital allocation (including active share repurchases), and the successful integration of the Theravance assets will be closely watched. Competitive threats from other HER2-directed therapies and ADC developers, and any clinical setbacks in early-stage programs, remain the principal risks to the consensus view.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SRS | 42.81 | 0.80 | +1.90% |
| ProShares UltraShort Real Estate (SRS) | |||
| GJS | 23.35 | 0.06 | +0.27% |
| Synthetic Fixed-Income Securities STRATS 2006-2 Goldman Sachs Group | |||
| AUGM | 34.85 | -0.05 | -0.16% |
| FT Vest U.S. Equity Max Buffer ETF - August (AUGM) | |||
| QEFA | 94.84 | -1.64 | -1.70% |
| State Street SPDR MSCI EAFE StrategicFactors ETF (QEFA) | |||
| WOOD | 61.27 | -1.25 | -1.99% |
| iShares Global Timber & Forestry ETF (WOOD) | |||
A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with REPL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then REPL could also see price increases.
| Ticker / NAME | Correlation To ZYME | 1D Price Change % | ||
|---|---|---|---|---|
| ZYME | 100% | -2.68% | ||
| REPL - ZYME | 46% Loosely correlated | -0.83% | ||
| DYN - ZYME | 44% Loosely correlated | -3.31% | ||
| BCYC - ZYME | 40% Loosely correlated | -4.92% | ||
| ENTA - ZYME | 40% Loosely correlated | -4.51% | ||
| VIR - ZYME | 40% Loosely correlated | -5.41% | ||
More | ||||
a company for cancer & autoimmune treatment
Industry Biotechnology
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ZYME advanced for three days, in 252 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for ZYME crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 72%.
ZYME may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 186 of 221 cases where ZYME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
The 10-day RSI Indicator for ZYME moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 53 similar instances where the indicator moved out of overbought territory. In 39 of the 53 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ZYME as a result. In 68 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for ZYME turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 39 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
ZYME moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZYME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. ZYME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 78 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.452) is normal, around the industry mean (3.596). P/E Ratio (-14.668) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (52.910) is also within normal values, averaging (443.347).
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZYME’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.